Representativeness of an HIV cohort of the sites from which it is recruiting: results from the Ontario HIV Treatment Network (OHTN) cohort study

BMC Medical Research Methodology

Mona R Loutfy¹  Sean B Rourke⁶  Jeff Cohen⁸  Irving Salit⁴  Curtis Cooper²  Sandra Blitz⁷  Ahmed M Bayoumi³  Sharon Walmsley⁴  Sandra Gardner⁹  Ann N Burchell⁹  DeSheng Su⁷  Janet Raboud⁵ 

[1] Maple Leaf Medical Clinic, Toronto, Ontario, Canada;The Ottawa Hospital Division of Infectious Diseases, The University of Ottawa, Ottawa, Ontario, Canada;Division of General Internal Medicine, Centre for Research on Inner City Health, The Keenan Research Centre in the Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, Ontario, Canada;Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada;Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada;Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada;Toronto General Research Institute, University Health Network, Room 13EN226, 200 Elizabeth St., Toronto, Ontario, M5G 2C4, Canada;Windsor Regional Hospital, Windsor, Ontario, Canada;Ontario HIV Treatment Network, Toronto, Ontario, Canada

关键词: Representativeness;    Generalizability;    HIV;    Selection bias;    Participation bias;   

Others  :  1126105
DOI  :  10.1186/1471-2288-13-31

 received in 2012-03-13, accepted in 2013-02-27,  发布年份 2013

【 摘 要 】

Background

Participation bias is a well-known phenomenon in epidemiologic research, where individuals consenting to research studies differ from individuals who are not able or willing to participate. These dissimilarities may limit the generalizability of results of research studies. Quantification of the participation bias is essential for the interpretation of research findings.

Methods

The Ontario HIV Treatment Network Cohort Study (OCS) is an ongoing open cohort study of HIV positive individuals receiving care at one of 11 sites in Ontario. OCS participants from 4 sites were compared to non-participants (those who declined or were not approached) at those sites with regard to gender, age, HIV risk factor, CD4 count and viral load (VL). Generalized logit regression models were used to identify predictors of declining to participate or not being approached to participate.

Results

Compared to participants (P) in the OCS, individuals who declined to participate (D) and those who were not approached (NA) were slightly younger (D:45, NA:44 vs P:46), less likely to be male (D: 71%, NA:75% vs P:88%), less likely to be Caucasian (D:41%, NA:57% vs P:72%) and less likely to be Canadian-born (D: 39%, NA: 52% vs P: 69%). Patients who were not approached to participate were less likely to have VL < 50 copies/mL than other patients (D: 75%, NA: 62%, P: 74%) and had lower CD4 counts than OCS participants (D: 450 cells/mm³, NA: 420 cells/mm³, P: 480 cells/mm³).

Conclusions

Significant demographic and clinical differences were found between OCS participants and non-participants. Extrapolation of research findings to other populations should be undertaken cautiously.

【 授权许可】

   
2013 Raboud et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Hagan H, McGough JP, Thiede H, Hopkins SG, Weiss NS, Alexander ER: Volunteer bias in nonrandomized evaluations of the efficacy of needle exchange programs. J Urban Health 2000, 77(1):103-112.
• [2]Carey MP, Senn TE, Vanable PA, Coury-Doniger P, Urban MA: Do STD clinic patients who consent to sexual health research differ from those who decline? Findings from a randomized controlled trial with implications for the generalizations of research results. Sex Transm Dis 2008, 35(1):73-77.
• [3]Campsmith ML, Goldbaum GM, Wood RM: Demographic and behavioral differences among participants, nonparticipants, and dropouts in a cohort study of men who have sex with men. Sex Transm Dis 1995, 22(5):312-316.
• [4]Friis-Moller N, Weber R, Reiss P: Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD Study. AIDS 2003, 17:1179-1193.
• [5]Chiesi A, Mocroft A, Dally LG: Regional survival differences across Europe in HIV positive people: The EuroSIDA study. AIDS 1999, 13(16):2281-2288.
• [6]Forrest DM, Seminari E, Hogg RS, Yip B, Raboud J, Lawson L: The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis 1998, 27(6):1379-1385.
• [7]Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, Sorensen HT: Cohort Profile: The Danish HIV Cohort Study. Int J Epidemiol 2009, 38(5):1202-1206.
• [8]Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D: Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009, 23:1163-1169.
• [9]Swiss HIV, Study C, Schoeni-Affolter F, Ledergerber B, Rickenbach M: Cohort Profile: the Swiss HIV Cohort Study. Int J Epidemiology 2010, 39(5):1179-1189.
• [10]Kaslow RA, Ostrow DG, Detels R: The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987, 126(2):310-318.
• [11]Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, Goulet J, Simberkoff M, Butt AA, Rimland D, Rodriguez-Barradas MC, Gibter CL, Oursler KAK, Brown S, Leaf DA, Goetz MB, Bryant K: Veterans Aging Cohort Study (VACS): overview and description. Med Care 2006, 44(8 Suppl 2):S13-S24.
• [12]Barkan SE, Melnick SL, Preston-Martin S: The Women’s Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998, 9(2):117-125.
• [13]Rourke S, Gardner S, Burchell AN, Raboud JM, Rueda S, Bayoumi A, Loutfy M, Cooper C: Cohort Profile: The Ontario HIV Treatment Network Cohort Study (OCS). International J Epidemiology 2012. Epub ahead of print
• [14]Furler MD, Einarson TR, Millson M, Walmsley S, Bendayan R: Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDS 2004, 18(4):215-228.
• [15]Andany N, Raboud JM, Walmsley S, Diong C, Rourke S, Rueda S, Rachlis A, Wobeser W, MacArthur R, Binder L, Rosenes R, Loutfy MR: Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. HIV Clin Trials 2011, 12(2):89-103.
• [16]Rothman KJ, Greenland S, Lash TL: Modern Epidemiology. 3rd edition. Philadelphia: Wolters Kluwer; 2008.
• [17]Senn TE, Carey MP, Vanable PA, Coury-Doniger P, Urban M: Even if you build it, we may not come: correlates of non-attendance at a sexual risk reduction workshop for STD clinic patients. AIDS Behav 2007, 11(6):864-871.
• [18]Johnson MO, Dilworth SE, Neilands TB, Chesney MA, Rotherman-Borus MJ, Remien RH, Weinhardt L, Ehrhardt AA, Morin SF, NIMH HLP Team: Predictors of attrition among high risk HIV-infected participants enrolled in a multi-site prevention trial. AIDS Behav 2008, 12(6):974-977.
• [19]Kuhns LM, Vazquez R, Ramirez-Valles J: Researching special populations: retention of Latino gay and bisexual men and transgender persons in longitudinal health research. Health Educ Res 2008, 23(5):814-825.
• [20]Vanable PA, Carey MP, Carey KB, Maisto SA: Predictors of participation and attrition in a health promotion study involving psychiatric outpatients. J Consult Clin Psychol 2002, 70(2):362-368.